You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Details for New Drug Application (NDA): 219714

✉ Email this page to a colleague

« Back to Dashboard

NDA 219714 describes SERTRALINE HYDROCHLORIDE, which is a drug marketed by Almatica, Appco, Novitium Pharma, Skg Pharma, Umedica, Zenara, Zydus Lifesciences, Aurobindo Pharma, Ranbaxy Labs Ltd, Strides Pharma, Accord Hlthcare, Ascent Pharms Inc, Chartwell Molecular, Granules, Heritage, Heritage Pharma Avet, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan Pharms Inc, Oxford Pharms, Pharmaco, Pharmobedient, Quagen, Reyoung, Sciegen Pharms, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Torrent Pharms, Tp Anda Holdings, and Zydus, and is included in thirty-seven NDAs. It is available from forty-eight suppliers. Additional details are available on the SERTRALINE HYDROCHLORIDE profile page.

The generic ingredient in SERTRALINE HYDROCHLORIDE is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.

Summary for 219714

Tradename:	SERTRALINE HYDROCHLORIDE
Applicant:	Novitium Pharma
Ingredient:	sertraline hydrochloride
Patents:	0

Pharmacology for NDA: 219714

Mechanism of Action	Cytochrome P450 2D6 Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for 219714

Antidepressive Agents
Serotonin Uptake Inhibitors

Suppliers and Packaging for NDA: 219714

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	CAPSULE;ORAL	219714	ANDA	ANI Pharmaceuticals, Inc.	70954-899	70954-899-10	30 CAPSULE in 1 BOTTLE (70954-899-10)
SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	CAPSULE;ORAL	219714	ANDA	ANI Pharmaceuticals, Inc.	70954-900	70954-900-10	30 CAPSULE in 1 BOTTLE (70954-900-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 150MG BASE
Approval Date:	Jan 20, 2026	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 200MG BASE
Approval Date:	Jan 20, 2026	TE:	AB	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.